KBY Biotech Indexv0.0.34
Search
← Pipeline|Lirarelsin

Lirarelsin

Approved
OBS-2472
By ObsEva (XOMA)
Source: Trial-derived·Trials: 4
Modality
Peptide
MOA
MDM2i
Target
GIP-R
Pathway
PD-1/PD-L1
Pancreatic CaMDS
Development Pipeline
Preclinical
~Oct 2009
→ ~Jan 2011
Phase 1
~Apr 2011
→ ~Jul 2012
Phase 2
~Oct 2012
→ ~Jan 2014
Phase 3
~Apr 2014
→ ~Jul 2015
NDA/BLA
~Oct 2015
→ ~Jan 2017
Approved
Apr 2017
→ Oct 2030
ApprovedCurrent
NCT05526644
1,727 pts·MDS
2021-02→TBD·Active
NCT04632291
2,998 pts·Pancreatic Ca
2021-02→2029-02·Terminated
NCT04624056
435 pts·Pancreatic Ca
2021-12→2025-01·Not yet recruiting
+1 more trial
6,355 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-01-111.2y agoPh3 Readout· Pancreatic Ca
2029-02-182.9y awayPh3 Readout· Pancreatic Ca
2030-10-124.5y awayPh3 Readout· Pancreatic Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Recruit…
Approved
Active
Approved
Termina…
Approved
Not yet…
Catalysts
Ph3 Readout
2025-01-11 · 1.2y ago
Pancreatic Ca
Ph3 Readout
2029-02-18 · 2.9y away
Pancreatic Ca
Ph3 Readout
2030-10-12 · 4.5y away
Pancreatic Ca
RecruitingActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
NCTPhaseIndicationStatusNEP
NCT05526644ApprovedMDSActive1727FEV1
NCT04632291ApprovedPancreatic CaTerminated2998PANSS
NCT04624056ApprovedPancreatic CaNot yet recr...435DAS28
NCT07425441ApprovedPancreatic CaRecruiting1195DOR
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-5094Johnson & JohnsonPhase 2/3GIP-REGFRi
DoxacapivasertibEli LillyPhase 3APOC3MDM2i
RHH-3592RochePhase 1/2GIP-RBCL-2i
AZN-5978AstraZenecaPhase 2/3GIP-RAHRant
BMY-8678Bristol-Myers SquibbApprovedRETMDM2i
IvotuximabGSKNDA/BLAGIP-RKRASG12Di
AMG-415AmgenPhase 1CDK2MDM2i
GIL-2037Gilead SciencesApprovedKRASG12DMDM2i
ElrarapivirRegeneronPhase 1GIP-RCl18.2
CapiglumideBioNTechPreclinicalCGRPMDM2i